This story was updated following CVS Health's earnings call Wednesday morning. | The company reported improvements in its ...

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...

The Pharmacy & Consumer Wellness segment at CVS Health CVS is showing strong momentum, driven by the company’s focus on operational excellence and technological upgrades that improve the customer ...

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

Louisiana has shifted one of its two large pharmacy benefits contracts for state employees away from CVS Health, but Gov. Jeff Landry and state lawmakers kept the most lucrative agreement with that ...

Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...

Here are four recent updates from CVS Health: 1. CVS Health subsidiary Omnicare has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Northern District of Texas. The filing follows ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

CVS Health projected double-digit earnings growth for 2026 on Wednesday after raising its 2025 profit forecast for the third ...